Sorry, you need to enable JavaScript to visit this website.

Skip to main content


Focus on Alzheimer’s Disease

Alzheimer’s Disease and Neurodegenerative Disorders
Our Areas of Interest for Collaboration



Nerve fibers
Nerve fibers

Disease- Modifying ActivitySymptomatic Treatment of Cognitive Impairment and Neuropsychiatric ConditionsBiomarkers and Diagnostics
  • Agents in preclinical stage or later should have preclinical validated in vivo, proof-of-concept data
    • Amyloid and tau modulators
    • Synaptic & cellular resilience
    • ApoE4
    • Neuroinflammation related pathways
    • Therapeutics targeting well-validated human genetic risk factors

Novel agents with Phase 2 proof-of- concept in neuropsychiatric symptoms or neuropsychiatric symptoms with cognitive impairment that exhibit superior efficacy to standard of care (e.g., antipsychotics, acetylcholinesterase inhibitors) as monotherapy or adjunctive therapy with synergistic efficacy.

  • Prognostic, diagnostic and disease progression biomarkers
  • Diagnostic imaging agents, including imaging of disease pathology, structural and functional MRI
  • Improved cerebrospinal fluid and blood biomarker assays